124 related articles for article (PubMed ID: 9049582)
1. Pharmacokinetic properties of YM17E, an inhibitor of acyl coenzyme A: cholesterol acyl transferase, and serum cholesterol levels in healthy volunteers.
Uchida T; Usui T; Watanabe T; Higuchi S; Nakata M; Maezawa K; Kikawa Y; Tsunoo M; Nakaya N; Goto Y
Eur J Clin Pharmacol; 1997; 51(5):399-406. PubMed ID: 9049582
[TBL] [Abstract][Full Text] [Related]
2. Disposition and metabolism of a novel diurea inhibitor of acyl CoA: cholesterol acyltransferase (YM17E) in the rat and dog.
Uchida T; Nakamura E; Usui T; Imasaki H; Kawakami R; Watanabe T; Higuchi S
Xenobiotica; 1994 Dec; 24(12):1223-36. PubMed ID: 7771109
[TBL] [Abstract][Full Text] [Related]
3. The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA: Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers.
Peck RW; Wiggs R; Posner J
Eur J Clin Pharmacol; 1995; 49(3):243-9. PubMed ID: 8666002
[TBL] [Abstract][Full Text] [Related]
4. In-vitro metabolism of YM17E, an inhibitor of acyl coenzyme A:cholesterol acyltransferase, by liver microsomes in man.
Uchida T; Watanabe T; Van Hoogdalem EJ; Higuchi S
J Pharm Pharmacol; 1996 Oct; 48(10):1049-56. PubMed ID: 8953507
[TBL] [Abstract][Full Text] [Related]
5. Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats.
Uchida T; Aoyama K; Watanabe T; Higuchi S
Atherosclerosis; 1998 Mar; 137(1):97-106. PubMed ID: 9568741
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs.
Kashiwa M; Masuyama Y; Miyauchi H; Uchida T; Naganuma S; Kakuta H; Terada M; Kiriyama T; Matsuda K; Ito N; Iizumi Y; Takenaka T
Jpn J Pharmacol; 1997 Jan; 73(1):41-50. PubMed ID: 9032133
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of a new inhibitor of acyl CoA:cholesterol acyltransferase, YM17E, and five metabolites using high-performance liquid chromatography with electrochemical detection.
Uchida T; Usui T; Watanabe T; Higuchi S
J Chromatogr; 1993 Mar; 613(1):179-83. PubMed ID: 8458898
[TBL] [Abstract][Full Text] [Related]
8. Metabolic N-demethylation of 1,3-bis[[1-cycloheptyl-3-(p- dimethylaminophenyl)ureido]methyl]benzene dihydrochloride, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor.
Uchida T; Usui T; Teramura T; Watanabe T; Higuchi S
Drug Metab Dispos; 1993; 21(3):524-9. PubMed ID: 8100510
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
10. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
[TBL] [Abstract][Full Text] [Related]
12. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
14. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327
[TBL] [Abstract][Full Text] [Related]
15. Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans.
Harris WS; Dujovne CA; von Bergmann K; Neal J; Akester J; Windsor SL; Greene D; Look Z
Clin Pharmacol Ther; 1990 Aug; 48(2):189-94. PubMed ID: 2199133
[TBL] [Abstract][Full Text] [Related]
16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
17. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
18. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
